Biotinylated Human LY6G6D Protein
Catalog No: LY6G6D-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human LY6G6D Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Asn20-Ser104 (UniProt accession: O95868).
Product Details
- Molecular Aliases
- Protein Ly6-D; C6orf23; G6D; MEGT1; NG25; Protein Ly6D
- Protein Length
- Asn20-Ser104
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 12.79 kDa. Due to glycosylation, the protein migrates to 15-20 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human LY6G6D on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human LY6G6D is greater than 90% as determined by SEC-HPLC.
Immobilized Biotinylated Human LY6G6D, His-Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-LY6G6D Antibody, hFc Tag with the EC50 of 4.4ng/ml determined by ELISA. (QC Test)
Loaded Anti-LY6G6D Antibody, hFc Tag on ProA-Biosensor can bind Biotinylated Human LY6G6D, His-Avi tag with an affinity constant of 1.51 nM as determined in BLI assay.
Background
LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
References
- Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, Thaler B, Walterskirchen C, Bauer K, Fabits M, Bergmann M, Binder C, Chetta PM, Vogt AB, Adam PJ. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. PMID: 36159851; PMCID: PMC9493073.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.